{"result": "(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is an organization that provides standards of medical care in diabetes and has published guidelines regarding obesity management and diabetes treatment.)\n##\n(\"entity\"<|>DIABETES MELLITUS TYPE 2<|>EVENT<|>Diabetes Mellitus Type 2 is a chronic condition that affects the way the body processes blood sugar (glucose) and can be managed through various treatments including metabolic surgery.)\n##\n(\"entity\"<|>SURGERY<|>EVENT<|>Surgery refers to medical procedures that involve the physical manipulation of tissues, which in this context relates to metabolic surgery aimed at treating diabetes.)\n##\n(\"entity\"<|>BARIATRIC SURGERY<|>EVENT<|>Bariatric surgery is a type of surgery that helps with weight loss and is often performed on individuals with obesity to improve health outcomes, including diabetes management.)\n##\n(\"entity\"<|>RUBINO F.<|>PERSON<|>Rubino F. is a researcher who has contributed to the literature on metabolic surgery and its effects on diabetes treatment.)\n##\n(\"entity\"<|>CUMMINGS DE<|>PERSON<|>Cummings DE is a researcher who has published work on metabolic surgery for the treatment of type 2 diabetes in obese individuals.)\n##\n(\"entity\"<|>SEEN-SECO-SEEDO-SED<|>ORGANIZATION<|>SEEN-SECO-SEEDO-SED is a collective of societies that have positioned themselves on metabolic surgery for patients with type 2 diabetes.)\n##\n(\"relationship\"<|>AMERICAN DIABETES ASSOCIATION<|>DIABETES MELLITUS TYPE 2<|>The American Diabetes Association provides guidelines and standards for the management of Diabetes Mellitus Type 2.<|>8)\n##\n(\"relationship\"<|>SURGERY<|>DIABETES MELLITUS TYPE 2<|>Surgery, particularly metabolic surgery, is a treatment option for managing Diabetes Mellitus Type 2.<|>7)\n##\n(\"relationship\"<|>BARIATRIC SURGERY<|>DIABETES MELLITUS TYPE 2<|>Bariatric surgery is specifically aimed at treating obesity, which is a significant factor in the management of Diabetes Mellitus Type 2.<|>7)\n##\n(\"relationship\"<|>RUBINO F.<|>BARIATRIC SURGERY<|>Rubino F. has conducted research on the effects of bariatric surgery on diabetes management.<|>6)\n##\n(\"relationship\"<|>CUMMINGS DE<|>BARIATRIC SURGERY<|>Cummings DE has published research on the role of bariatric surgery in treating type 2 diabetes in obese individuals.<|>6)\n##\n(\"relationship\"<|>SEEN-SECO-SEEDO-SED<|>BARIATRIC SURGERY<|>SEEN-SECO-SEEDO-SED has issued positioning documents regarding the use of metabolic surgery for diabetes treatment.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ./día de metformina,\n         La cirugía metabólica debe realizarse en centros experimentados con un alto volumen de                                                           cuando quizás antes de la cirugía estaba con más de 100 UI de insulina y una HbA1c del 9%.\n         cirugías y con equipos multidisciplinares en el manejo de la diabetes y la cirugía.                                                              NOTA: mejor emplear el término “remisión”, porque la diabetes, como todas las enfermeda-\n         Las evidencias científicas           de que la cirugía metabólica facilitaba la remisión de la DM2                                               des crónicas, se controla, pero no se “cura” (se curan los procesos agudos, como una gripe,\n         tienen más de 10 años de constancia, pero la ADA no se ha hecho eco hasta recientemente,                                                         una apendicitis…).\n         una vez se ha tenido constancia reiterada de mejoría o remisión de la DM2 con cirugía en\n         ensayos clínicos aleatorizados (dieta vs. cirugía).                                                                                              Referencias:\n                                                                                                                                                          • Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, et al. How do we define cure of diabetes? Diabetes Care.\n                                                                                                                                                            2009;32(11):2133-5.\n         Referencias:                                                                                                                                     • Ramos-Levi AM, Matia P, Cabrerizo L, Barabash A, Sanchez-Pernaute A, Calle-Pascual AL, et al. Statistical models to predict type 2\n         • American Diabetes Association. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes                    diabetes remission after bariatric surgery. J Diabetes. 2014;6(5):472-7.\n           2018. Diabetes Care. 2018;41(Suppl 1):S65-S72.                                                                                                 • Ramos-Levi AM, Sanchez-Pernaute A, Cabrerizo L, Matia P, Barabash A, Hernandez C, et al. Remission of type 2 diabetes mellitus\n         • Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018;61(2):257-64.             should not be the foremost goal after bariatric surgery.\n         • Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Metabolic Surgery in the Treatment Algorithm for Type 2                 Obes Surg. 2013;23(12):2020-5.\n           Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861-77.\n         • Rubio MA, Monereo S, Lecube A, Resa J, Masdevall C, de la Cruz Vigo F, et al. Documento de posicionamiento de las Sociedades\n           SEEN-SECO-SEEDO-SED sobre cirugía metabólica para pacientes con diabetes mellitus tipo 2. Endocrinol Nutr. 2013;60(10):547-8.\n                                                                                                                                                 8.2 Casos clínicos. Caso clínico 1\n     16  ¿Cuál de las siguientes respuestas define la remisión completa de la diabetes\n         mellitus tras cirugía metabólica?                                                                                                         17     ¿Qué tratamiento farmacológico pondría para su diabetes?\n         A. Una HbA1c < 6%.                                                                                                                               A. Iniciaría tratamiento con fármacos glucosúricos tipo iSLGT2 para mejorar el control\n         B. Una HbA1c < 6,5% y glucemia < 126 mg/dl, en ausencia de medicación durante un año.                                                                 glucémico.\n         C. Una HbA1c en rango de normalidad (normalmente HbA1c < 6%) y glucemia < 100 mg/dl,                                                             B. Añadiría una sulfonilurea de tercera generación en unidosis diaria para mejorar el control\n             en ausencia de medicación durante un año.                                                                                                         metabólico de su diabetes por el efecto hipoglucemiante de este grupo terapéutico.\n         D.  Una HbA1c < 6% o una glucemia < 100 mg/dl.                                                                                                   C. Añadiría un agonista del receptor de GLP-1, pues podría favorecer una mayor pérdida\n                                                                                                                                                               de peso con respecto a otros hipoglucemiantes no insulínicos.\n         COMENTARIO                                                                                                                                       D.   Deberíamos añadir algún tipo de gliptina, que tiene un perfil de seguridad muy amplio.\n         Para hablar de remisión completa de la DM2, el paciente debe estar sin medicación durante\n         al menos un        año tras la cirugía metabólica y cumpliendo además                        dos requisitos: que la                              COMENTARIO\n         HbA1c esté en el rango de normalidad (a efectos prácticos también se considera HbA1c <                                                           La paciente tiene varios objetivos para controlar (diabetes, hipertensión, dislipidemia, po-\n         6%) y que la glucemia también esté por debajo de 100 mg/dl\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}